Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2019 on file Net Income-$4.96M-$4.96MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,952,730N/M Operating Cash Flowderived-$4,525,408N/M Free Cash Flowderived-$4,601,954N/M ended Dec 31, 2020 · filed Mar 31, 2021 · 90 d after period end